Hemonc simplified

This podcast is all about hematology and has simplified the subject matter for medical students, residents, and hematologists. This podcast is for educational purposes only and does not constitute medical advice. Consult your healthcare provider for personal medical concerns

Hemonc simplified is a general podcast hosted by Unknown Host, with 0 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts Hemonc simplified, a general show with 0 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #4

  004. Flow cytometry demystified

  Aug 25, 202620 minS1

  <p>Ready to master the ultimate diagnostic tool in hematopathology? In this episode of HemOnc Simplified, we crack open the flow cytometer to turn complex scatter plots and antibody markers into high-yield, intuitive clinical frameworks.</p><p>Whether you are preparing for your USMLE exams, pathology boards, or clinical hematology rotations, this episode breaks down the core concepts you absolutely must know:</p>The "City Analogy": Understand the fundamental difference between Flow Cytometry and Immunohistochemistry (IHC). Flow cytometry "demolishes the city" by dissociating the tissue into individual cell suspensions to interview thousands of cellular residents, while IHC "leaves the city...

  ListenShow Notes
• 

  Episode #3

  003. Immune checkpoint inhibitors and related side effects

  Jul 17, 202621 minS1

  <p>"HemOnc Simplified: Navigating the 2026 NCCN Guidelines for Immunotherapy Toxicities."</p><p>How do we manage the "collateral damage" when the immune system turns against the body? In this episode, we dive deep into the 2026 NCCN Clinical Practice Guidelines for the Management of Immune Checkpoint Inhibitor-Related Toxicities.</p><p>In this episode, we cover:</p>The Biology of "Releasing the Brakes": Why blocking CTLA-4 and PD-1 proteins allows T cells to attack cancer but also triggers inflammatory immune-related adverse events (irAEs).The "Big Two" (Skin & Gut): Management protocols for maculopapular rashes and colitis, including the 2026 criteria for holding therapy and...

  ListenShow Notes
• 

  Episode #2

  002. Rewriting the Genetic Rulebook for Leukemia

  Jul 14, 202625 minS1

  <p>The "genetic rulebook" for Acute Myeloid Leukemia (AML) has undergone a fundamental transformation, shifting the focus of diagnosis and treatment from how cells look under a microscope (morphology) to their underlying molecular and cytogenetic signatures. This evolution is codified in the competing 2022 classification systems from the World Health Organization (WHO) and the International Consensus Classification (ICC), as well as the updated 2022 European LeukemiaNet (ELN) risk stratification.</p><p>One of the most significant changes in the modern rulebook is the de-emphasis of the traditional 20% blast threshold for diagnosis.</p>WHO 2022: Eliminates the blast threshold entirely for specific entities, such...

  ListenShow Notes
• 

  Episode #1

  001. AML Management and Board Review Strategy

  Jul 13, 202624 minS1

  <p>Welcome to this educational podcast on Acute Myeloid Leukemia (AML).</p><p>The information presented in this podcast is intended solely for educational and informational purposes. It is based on current medical literature, published clinical guidelines, and the source material used in preparing this episode. Medical knowledge continues to evolve, and recommendations may change as new evidence becomes available.</p><p>This podcast is not intended to replace professional medical advice, diagnosis, or treatment. Healthcare professionals should use their own clinical judgment and consult the latest guidelines, institutional protocols, and prescribing information before making patient care decisions.</p><p>...

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.